AdventHealth
Oncology
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Developmental Therapeutics Highlights
FEATURING
Guru Sonpavde
- 273 views
- October 25, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 158 views
- September 24, 2024
2024 ASCO® Annual Meeting Insights Hub
Developmental Therapeutics Highlights From ASCO® 2024
FEATURING
Guru Sonpavde
- 539 views
- July 5, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
Bladder Cancer Highlights From ASCO® 2024
FEATURING
Guru Sonpavde
- 1,547 views
- June 10, 2024
- 11
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New Treatments
FEATURING
Guru Sonpavde
- 2,013 views
- April 16, 2024
- 11
AdventHealth
FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advanced Urothelial Carcinoma
FEATURING
Guru Sonpavde
- 274 views
- March 11, 2024
- 1
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcinoma"
FEATURING
Guru Sonpavde
- 417 views
- February 6, 2024
- 8
Insights from 2023 ESMO Annual Meeting
ESMO23 Highlights in Urothelial Carcinoma
FEATURING
Guru Sonpavde,
Bradley McGregor
- 243 views
- November 28, 2023
- 1
Insights from 2023 ESMO Annual Meeting
Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting EV302 and CheckMate 901
FEATURING
Guru Sonpavde
- 854 views
- October 30, 2023
- 3
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Key Bladder Cancer/Urothelial Carcinoma Updates"
FEATURING
Guru Sonpavde
- 376 views
- June 16, 2023
- 2
ESMO 2022 Conference Coverage
ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations
FEATURING
Guru Sonpavde
- 810 views
- September 16, 2022
- 1
SABCS 2022 Conference Coverage
Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study
FEATURING
Wassim Mchayleh
- 305 views
- February 7, 2023
- 1